All In Biotech

Drug Trial Radar · NCT03605862

Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Last checked: Nov 20, 2026Latest source record: Apr 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,756 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,756

Actual

Start

Sep 11, 2018

Primary completion

Feb 4, 2019

Study completion Feb 4, 2019

Sponsor

Lead sponsor
Romark Laboratories L.C.Industry
Sponsor type
Industry
First posted
Jul 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trial to evaluate efficacy and safety of nitazoxanide in the treatment of colds due to Enterovirus/Rhinovirus infection

Conditions

  • Enterovirus
  • Rhinovirus

Interventions

  • NitazoxanideDrug

    Nitazoxanide 600 mg administered orally twice daily for five days

  • PlaceboDrug

    Placebo administered orally twice daily for five days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time From First Dose to Symptom Response Over 21 Days of Follow up Based Upon the FLU-PRO Instrument (Novel Endpoint)Time frame: Up to 21 days

Locations

45 sites in 2 countries. Site status is shown where the registry gives one.

  • Vanguard Study Site

    Birmingham, Alabama

  • Vanguard Study Site

    Birmingham, Alabama

  • Vanguard Study Site

    Pelham, Alabama

  • Vanguard Study Site

    Hot Springs, Arkansas

  • Vanguard Study Site

    Anaheim, California

  • Vanguard Study Site

    Westminster, California

  • Vanguard Study Site

    Wilmington, California

  • Vanguard Study Site

    Miami, Florida

  • Vanguard Study Site

    Miami, Florida

  • Vanguard Study Site

    Miami, Florida

  • Vanguard Study Site

    Orlando, Florida

  • Vanguard Study Site

    Tampa, Florida

  • Vanguard Study Site

    Stockbridge, Georgia

  • Vanguard Study Site

    Blackfoot, Idaho

  • Vanguard Study Site

    Meridian, Idaho

  • Vanguard Study Site

    Nampa, Idaho

  • Vanguard Study Site

    Evanston, Illinois

  • Vanguard Study Site

    Valparaiso, Indiana

  • Vanguard Study Site

    Louisville, Kentucky

  • Vanguard Study Site

    New Orleans, Louisiana

  • Vanguard Study Site

    New Orleans, Louisiana

  • Vanguard Study Site

    Baltimore, Maryland

  • Vanguard Study Site

    St Louis, Missouri

  • Vanguard Study Site

    Missoula, Montana

  • Vanguard Study Site

    Bellevue, Nebraska

  • Vanguard Study Site

    Las Vegas, Nevada

  • Vanguard Study Site

    Brooklyn, New York

  • Vanguard Study Site

    Raleigh, North Carolina

  • Vanguard Study Site

    Cincinnati, Ohio

  • Vanguard Study Site

    Cleveland, Ohio

  • Vanguard Study Site

    Columbus, Ohio

  • Vanguard Study Site

    Dayton, Ohio

  • Vanguard Study Site

    Medford, Oregon

  • Vanguard Study Site

    East Providence, Rhode Island

  • Vanguard Study Site

    Jackson, Tennessee

  • Vanguard Study Site

    Milan, Tennessee

  • Vanguard Study Site

    Austin, Texas

  • Vanguard Study Site

    Carrollton, Texas

  • Vanguard Study Site

    Houston, Texas

  • Vanguard Study Site

    McAllen, Texas

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.